10-Q: International Isotopes Inc. Reports Mixed Results in Q2 2024, Revenue Growth in Key Segments Offset by Supply Chain Issues

International Isotopes Inc. saw a slight overall revenue increase in Q2 2024, with growth in Theranostics and Cobalt products offset by a significant decline in Nuclear Medicine Standards due to a global isotope shortage.

Summary

• International Isotopes Inc. (INIS) reported a net loss of $387,496 for the six months ended June 30, 2024, compared to a net loss of $411,356 for the same period in 2023.
• The company's revenue for the first six months of 2024 was $6,073,691, a slight decrease from $6,201,700 in the same period of 2023.
• INIS experienced a 25% increase in revenue in its Theranostics Products segment and a 32% increase in its Cobalt Products segment for the three months ended June 30, 2024.
• The Nuclear Medicine Standards segment saw a 56% decrease in revenue for the three months ended June 30, 2024, due to a global shortage of Cobalt-57 isotope.
• Operating expenses increased by 6% for the three months ended June 30, 2024, primarily due to increased professional expenses and research and development costs.
• The company expects cash from operations, equity or debt financing, and its current cash balance will be sufficient to fund operations for the next twelve months.
• INIS has a contract with the U.S. Department of Energy (DOE) for the production of high specific activity cobalt, which is set to expire in October 2024, and the company is working on an extension.
• The company entered into a definitive agreement to sell its Fluorine Products segment and the Planned Uranium De-Conversion Facility for approximately $12.5 million, with closing expected within 12 to 24 months.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive revenue growth in some segments offset by significant challenges in others. The company is facing supply chain issues and increased operating expenses, but also has growth opportunities and a strategic partnership. The sentiment is neutral to slightly negative due to the net loss and revenue decrease.

Positives

• The Theranostics Products segment experienced a significant revenue increase of 25% for the three months ended June 30, 2024, indicating strong demand for its products.
• The Cobalt Products segment also saw a substantial revenue increase of 32% for the three months ended June 30, 2024, demonstrating growth in this area.
• The company's gross profit increased by 9% for the three months ended June 30, 2024, showing improved profitability.
• The company has secured a strategic development and distribution agreement with Alpha Nuclide Inc for the Chinese market.
• The company expects a revenue catch-up in the second half of 2024 and potentially into the first quarter of 2025 as they fulfill backlogged orders due to the Cobalt-57 shortage.

Negatives

• The Nuclear Medicine Standards segment experienced a significant revenue decrease of 56% for the three months ended June 30, 2024, due to a global shortage of Cobalt-57 isotope.
• Operating expenses increased by 6% for the three months ended June 30, 2024, impacting overall profitability.
• The company incurred a $45,000 NRC penalty for a violation that occurred in 2022.
• The company reported a net loss of $387,496 for the six months ended June 30, 2024.
• The company's overall revenue decreased slightly by 2% for the six months ended June 30, 2024.

Risks

• The company's production of High Specific Activity Cobalt is dependent on the U.S. Department of Energy (DOE), and its contract is set to expire in October 2024.
• Sales of Theranostics products are dependent on a few key suppliers, and interruptions could negatively impact sales.
• The Nuclear Medicine Reference and Calibration Standard products are dependent on radioisotopes from several suppliers, and a loss of any supplier could cause delays or loss of sales.
• The company's business segments involve handling radioactive material, requiring an operating license from the NRC and specially trained staff.
• The company's future liquidity and capital funding requirements depend on various factors, and there is no assurance that additional capital will be available on acceptable terms.

Future Outlook

The company expects continued sales growth for its Theranostics products, primarily from the sale of its generic sodium iodide I-131 drug product and new sales of theranostic API product. The company also expects a revenue catch-up in the second half of 2024 and potentially into the first quarter of 2025 as they fulfill backlogged orders due to the Cobalt-57 shortage. The company anticipates commercialization of medical devices starting later in 2024. The company expects that cash from operations, equity or debt financing, and its current cash balance will be sufficient to fund operations for the next twelve months.

Management Comments

• The company continued its focus on its strongest long-standing core business segments which consist of its Theranostics Products, Cobalt Products, and Nuclear Medicine Standards.
• The company has begun to focus on the start-up of its Medical Device segment.
• The company is currently working on an extension to its contract with the DOE for the production of high specific activity cobalt.
• The company expects to close the agreement to sell its Fluorine Products segment within 12 to 24 months of signing.

Industry Context

The company operates in the niche market of nuclear medicine and radiopharmaceuticals, facing competition from both established players and emerging companies. The global shortage of Cobalt-57 isotope highlights the vulnerability of the industry to supply chain disruptions. The company's strategic development and distribution agreement with Alpha Nuclide Inc for the Chinese market is a move to expand its reach and diversify its revenue streams. The company's focus on its core business segments and the development of new products in the medical device segment are aligned with industry trends towards personalized medicine and advanced diagnostics.

Comparison to Industry Standards

• The company's revenue growth in the Theranostics and Cobalt segments is positive, but the significant decline in the Nuclear Medicine Standards segment due to the Cobalt-57 shortage is a concern.
• Compared to other companies in the radiopharmaceutical industry, INIS's reliance on a few key suppliers for raw materials and isotopes is a risk that needs to be mitigated.
• The company's operating expenses are relatively high compared to some of its peers, which impacts its profitability.
• The company's strategic development and distribution agreement with Alpha Nuclide Inc is a positive step towards expanding its market reach, similar to other companies that have formed partnerships to enter new markets.
• The company's focus on developing new products in the medical device segment is in line with industry trends towards diversification and innovation.

Legal Proceedings

• The company paid an NRC penalty of $45,000 in the three months ended June 30, 2024, for a violation that occurred in 2022.

Related Party Transactions

• The company has promissory notes with its former Chairman of the Board, its Chief Executive Officer and Chairman of the Board, and four major shareholders.
• Some holders of the Series C Preferred Stock elected to settle their dividend payments with shares of the company's common stock in lieu of cash.

Stakeholder Impact

• Shareholders may be concerned about the net loss and the decrease in revenue for the six months ended June 30, 2024.
• Employees may be affected by the company's focus on core business segments and the start-up of the Medical Device segment.
• Customers of the Nuclear Medicine Standards segment may have experienced delays due to the global shortage of Cobalt-57 isotope.
• Suppliers may be impacted by the company's dependence on a few key suppliers for raw materials and isotopes.
• Creditors may be concerned about the company's debt and liquidity.

Next Steps

• The company will continue to focus on its core business segments, including Theranostics, Cobalt, and Nuclear Medicine Standards.
• The company will work on the start-up of its Medical Device segment and commercialization of new products.
• The company will work on an extension to its contract with the DOE for the production of high specific activity cobalt.
• The company will work towards closing the agreement to sell its Fluorine Products segment and the Planned Uranium De-Conversion Facility.
• The company will continue to fulfill backlogged orders in the Nuclear Medicine Standards segment as the Cobalt-57 supply chain normalizes.

Key Dates

Keywords

Isotopes, Nuclear Medicine, Theranostics, Cobalt, Radiochemicals, Medical Devices, Radioisotopes, NRC, DOE, Iodine-131